Review An Oregon federal judge on Wednesday reluctantly stayed a high-profile lawsuit brought by children accusing the federal government of making climate change worse, fully pausing the case so her refusal to dismiss it can be reviewed by the Ninth Circuit, which recently stayed an already-delayed trial in the suit. Securities and Exchange Commission in a related bribery matter cancels its obligation.
On the call, we will also discuss second-quarter non-GAAP operating expense. Please see the presentation accompanying the call for further information and reconciliation of this measure. With that, I'll turn the call over to Craig. I'll start today's call with an update of the status of the strategic review that we initiated earlier this year.
I'll then provide an update on our complex generic products and biosimilar programs and then provide highlights from our novel drug pipeline for autoimmune disease. She will discuss our second-quarter financial results.
We'll then open the call for questions. I'll begin with our strategic review. Earlier this year, we announced that we had initiated a strategic review of our business to address the revenue uncertainty related to the late launch of Glatopa 40 milligram and the funding challenges we face in advancing our broad portfolio.
The goal of the strategic review is to assess different options that will allow us to reduce costs and focus on the assets in our pipeline with the highest potential, specifically, to redirect spending to our novel drug candidates for autoimmune indications.
We have been actively evaluating a wide range of options, including additional collaborative partnerships; slowing the pace of development of our biosimilar programs, which we've already done; selling one or more of our biosimilar assets, such as M, our wholly owned biosimilar HUMIRA asset; and implementing additional cost-reduction strategies.
It's important to note that the sale of the company has not been a focus of this strategic review, and we are not in discussions for the sale of the company as a whole. In terms of timing, we hope to be able to complete the strategic review and provide an update on this call.
However, we are not yet there due to the complexity of the process and the range of potential outcomes. Story Continues Please note that we are working diligently to complete the review.
We have started the strategic review with a goal of maximizing long-term shareholder value without the need for significant shareholder dilution in the near term. While we believe this goal is within reach, the outcome of the review could alter this goal.
We currently anticipate that we will complete our strategic review in the coming weeks, and we do not intend to discuss or disclose further developments during this process until appropriate. I'll now discuss our complex generics, starting with Glatopa.
Sandoz has ramped up the supply of Glatopa 40 milligram and expects continued adoption as the year progresses. As anticipated, competition in this market has been fierce due to growing pricing pressure from Mylan and Teva.
The glatiramer acetate market is responding to competition as expected, with increased pricing pressure from customers. We expect that as contract come up for bid, market share will continue to grow, and we believe that Sandoz understands the market and how to operate successfully in this environment.
Given these market dynamics, we believe that profit share revenue from our Glatopa products will be somewhat unpredictable and has the potential to vary from quarter to quarter.
Our internal revenue estimates for Glatopa remain conservative. However, we believe this revenue stream will continue to provide important nondilutive financing for our company into the foreseeable future. Before I move on to our broader portfolio, I wanted to provide a brief update on Enoxaparin.
In June, Sandoz alerted the FDA and its customers that it will be discontinuing the supply of the Enoxaparin injection product.
As a reminder, we have recorded minimal to no revenues for Enoxaparin over the past few years and no longer consider Enoxaparin's results as material for the company. Turning now to the patent litigation against Amphastar following the U.
District Court of Massachusetts' final judgment finding that our U. Amphastar moved to seek damages under the bond posted in connection with the preliminary injunction granted in On July 16,the U. District Court of Massachusetts denied Amphastar's motion and allowed our motion to defer consideration until the exhaustion of all appeals.
We have appealed the case to the court of appeals for the federal circuit and opening briefs have been submitted. I'll now turn to our biosimilar programs, and I'll start with M, our wholly owned biosimilar Humira candidate.GSK's consumer products include Tums, dental care products Aquafresh and Sensodyne, and smoking-cessation products NicoDerm and Nicorette.
In GSK bought Novartis' Vaccines and Consumer Health business, and sold its cancer drugs business to the same company.
Welcome to Value Stock Players The Ultimate VALUE INVESTING website for investors seeking outstanding stock market performance. We are an unbiased, independent subscription based stock selection service.
An Analysis of GlaxoSmithKline The business that I have done research into is GlaxoSmithKline. This company is a globalised research-based pharmaceutical public limited company. I started using Twitter the day the CA3blog site crashed.
In September of last year, I wrote something provocative here about a book by Judge Posner (“batshit crazy”) that got a bazillion hits from readers on Twitter, enough hits to bring down the blog’s website. Until that day I’d been a proud Twitter hold-out, but crashing my humble blog got my attention.
Find the latest business news on Wall Street, jobs and the economy, the housing market, personal finance and money investments and much more on ABC News. Shareholder Value and Current Financial Crisis: An analysis of the Relationship INTRODUCTION Corporate governance in a particular firm is inevitable for its administration, policy making and overall health.
In other words, ‘Corporate governance affects the development and functioning of capital markets and exerts a strong influence on resource allocation.’.